The Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, was created to conduct studies of treatments for neurological diseases through partnerships with academia, private foundations and industry. Funded by the National Institutes of Health's National Institute of Neurological Disorders and Stroke (NINDS), NeuroNEXT was designed to:

  • Increase the efficiency of clinical trials
  • Expand the capability of NINDS to test promising new therapies
  • Respond quickly as opportunities arise to test promising new treatments for people with neurological disorders

Working with NeuroNEXT is a cooperative venture between NINDS, the Network coordinating centers, and the academic, small business or industry collaborator. The Network provides a robust, standardized and accessible infrastructure to facilitate the rapid development and implementation of protocols in neurological disorders, in both adult and pediatric populations. The network includes clinical sites, a Clinical Coordinating Center and a Data Coordinating Center.

The NeuroNEXT Network consists of a Clinical Coordinating Center (CCC) at Massachusetts General Hospital, a Data Coordinating Center (DCC) at the University of Iowa, and 25 clinical sites throughout the country. Since 2011, we have been working together to improve productivity and expedite therapy development for neurological disorders. Features of the Network, including a Central IRB and a standardized Master Trial Agreement, are designed to efficiently conduct Phase II Clinical Trials. Studies in the Network are expected to take advantage of the experienced CCC and DCC, who work with investigators through the life-cycle of their project, as well as the well-trained clinical sites located throughout the US. Our funding comes from the National Institute of Neurological Disorders and Stroke (NINDS), and we work closely with NINDS representatives in all our undertakings.

For more information, view our full website.